Eli Lilly and Company Website

Eli Lilly and Company

NYSE-LLY

Company Overview

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

  • Name

    Eli Lilly and Company

  • CEO

    David A. Ricks

  • Website

    www.lilly.com

  • Sector

    Pharmaceuticals

  • Year Founded

    1876

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Bulls Say

  • Lilly's strong leadership in weight-loss drugs should drive industry-leading growth with approved drugs and well-positioned next-generation weight-loss drugs in the pipeline.

  • Lilly's cancer drug Verzenio reported strong data in early-stage breast cancer, opening up the strong potential in this multibillion-dollar market.

  • Lilly has launched a new Alzheimer’s drug (Kisunla/donanemab) that could become a major blockbuster, especially since few treatment options exist for the disease.

Bears Say

  • The risks to success for Alzheimer’s drug Kisunla remain high because of bottlenecks in patient diagnosis, required scans and monitoring, and competition.

  • Several of Lilly's next-generation cardiometabolic drugs could lead to cannibalization of current approved Lilly drugs.

  • Competition to weight-loss drug Zepbound could significantly increase over the next three years, from established competitor Novo Nordisk as well as new entrants.

Source: Morningstar Analysis - Nov 07, 2025

What's happening

Nov 5, 2025 - Dec 5, 2025

Eli Lilly's Stock Soars Amid FDA Approval and Strategic Initiatives

  • Eli Lilly received expanded FDA approval for its cancer drug Jaypirca, enhancing treatment options for patients.
  • The company announced strategic collaborations to improve medication access while investing in production capabilities.
  • Despite competitive pressures from Novo Nordisk, investor sentiment remains optimistic about LLY's growth potential.

Over the past month, Eli Lilly and Company (LLY) has demonstrated a strong stock performance with an increase of 13.9%. This significant rise notably surpassed the S&P 500’s return of just 1.3%, resulting in an impressive outperformance of 12.7% relative to the index. Investor confidence appears robust as LLY navigates competitive challenges within the pharmaceutical sector.

A primary catalyst for this positive momentum was LLY's announcement regarding expanded FDA approval for its cancer drug Jaypirca, which now allows earlier treatment interventions for chronic lymphocytic leukemia and small lymphocytic lymphoma patients. This development underscores Lilly’s commitment to improving patient care options and has led analysts to express favorable sentiments about its potential revenue impact. Additionally, anticipation surrounding upcoming presentations at major conferences has further fueled optimism among investors regarding LLY's innovative pipeline.

However, some bearish sentiments emerged during this period due to social media discussions highlighting significant price target updates amid competition with Novo Nordisk (NVO). Reports indicated that NVO had reduced prices on its obesity drugs, raising concerns over pricing strategies within the weight-loss medication market where both companies are fierce competitors. Furthermore, insider selling activity raised caution among investors as it may signal apprehension amidst increasing competition.

Despite these challenges, Eli Lilly adopted a proactive stance by announcing strategic collaborations aimed at expanding access to their medications while also investing heavily in new facilities designed to enhance production capabilities. These initiatives align with broader trends toward affordability and accessibility in healthcare and are expected to bolster long-term growth prospects.

Overall, Eli Lilly not only outperformed relative to the S&P but also exceeded expectations against the Health Care sector (XLV), achieving a remarkable excess return of 7.8%. Investors remain optimistic about Eli Lilly’s future trajectory given its solid fundamentals and strategic positioning within an evolving pharmaceutical landscape.

NYSE:LLY